Is mavacamten on the market?

Mavacamten is a novel myosin inhibitor indicated for the treatment of symptomatic adults with New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (HCM). The drug was approved by the U.S. Food and Drug Administration (FDA) in 2022, becoming one of the first myosin inhibitors for use in humans. The approval provides a new treatment option for patients with HCM, allowing it to be applied clinically.

In addition toFDA approval, Mavakate also received approval from Health Canada in October 2022 and the European Medicines Agency (EMA) in July 2023. The recognition of the drug in these countries and regions further proves its clinical effectiveness and safety. It is worth mentioning that Mavaceta is expected to be approved by the China National Medical Products Administration in April 2024 and be launched under the trade names of Mefanto and CAMZYOS. The dosage forms include 2.5 mg, 5 mg, 10 mg and 15 mg capsules, which will enable more patients to benefit.

Mavacatel’s launch is based on data from the Phase III Explorer-HCM trial. According to study results, at baseline, approximately 73% of randomized patients were assessed as NYHA class II and 27% as NYHA class III, with a mean left ventricular ejection fraction (LVEF) of 74% and a mean Valsalva left ventricular outflow tract (LVOT) gradient of 73 mm Hg. This basic data lays a solid foundation for subsequent evaluation of efficacy.

At week 30, 37% of patients receiving Mavacartide achieved the pre-specified composite primary endpoint, while only 17% of patients in the placebo group achieved the same improvement. This significant difference (19%, 95% CI: 9.30; p=0.0005) indicates that Mavacartide has significant efficacy in improving patients' exercise capacity and symptoms. In addition, patients treated with Mavacartide also showed greater improvements in all secondary endpoints, further solidifying its effectiveness.

Reference materials:https://www.drugs.com/newdrugs/fda-approves-camzyos-mavacamten-symptomatic-nyha-class-ii-iii-obstructive-hypertrophic-5825.html